Cargando…
La hidroxicloroquina como fármaco fundamental en dermatología y su papel controvertido en la COVID-19
Hydroxychloroquine is an antimalarial drug with immunomodulatory, anti-inflammatory, antibacterial, and antiviral properties. It has a good safety profile, can be used in children and in pregnant and breastfeeding women, and does not suppress the immune system. Regular screening for retinopathy, one...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AEDV. Published by Elsevier España, S.L.U.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326180/ https://www.ncbi.nlm.nih.gov/pubmed/34366433 http://dx.doi.org/10.1016/j.ad.2021.07.005 |
_version_ | 1783731724278038528 |
---|---|
author | Morgado-Carrasco, D. Ibaceta-Ayala, J. Piquero-Casals, J. |
author_facet | Morgado-Carrasco, D. Ibaceta-Ayala, J. Piquero-Casals, J. |
author_sort | Morgado-Carrasco, D. |
collection | PubMed |
description | Hydroxychloroquine is an antimalarial drug with immunomodulatory, anti-inflammatory, antibacterial, and antiviral properties. It has a good safety profile, can be used in children and in pregnant and breastfeeding women, and does not suppress the immune system. Regular screening for retinopathy, one of the drug's most feared adverse effects, is necessary. Hydroxychloroquine is a widely used, essential drug in dermatology. Clinical response rates are good in lupus erythematous, where it is a first-line therapy, as well in numerous autoimmune/inflammatory diseases, including lichen planus, polymorphic light eruption, porphyria cutanea tarda, granuloma annulare, and sarcoidosis. In 2020, it was widely prescribed both to prevent and to treat COVID-19 caused by SARS-CoV-2. Its increased use led to serious supply shortages and in some cases stocks were entirely depleted. Recent meta-analyses have concluded that hydroxychloroquine is ineffective against COVID-19 and have advised against its use. |
format | Online Article Text |
id | pubmed-8326180 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | AEDV. Published by Elsevier España, S.L.U. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83261802021-08-02 La hidroxicloroquina como fármaco fundamental en dermatología y su papel controvertido en la COVID-19 Morgado-Carrasco, D. Ibaceta-Ayala, J. Piquero-Casals, J. Actas Dermosifiliogr Dermatología Práctica Hydroxychloroquine is an antimalarial drug with immunomodulatory, anti-inflammatory, antibacterial, and antiviral properties. It has a good safety profile, can be used in children and in pregnant and breastfeeding women, and does not suppress the immune system. Regular screening for retinopathy, one of the drug's most feared adverse effects, is necessary. Hydroxychloroquine is a widely used, essential drug in dermatology. Clinical response rates are good in lupus erythematous, where it is a first-line therapy, as well in numerous autoimmune/inflammatory diseases, including lichen planus, polymorphic light eruption, porphyria cutanea tarda, granuloma annulare, and sarcoidosis. In 2020, it was widely prescribed both to prevent and to treat COVID-19 caused by SARS-CoV-2. Its increased use led to serious supply shortages and in some cases stocks were entirely depleted. Recent meta-analyses have concluded that hydroxychloroquine is ineffective against COVID-19 and have advised against its use. AEDV. Published by Elsevier España, S.L.U. 2022-02 2021-08-02 /pmc/articles/PMC8326180/ /pubmed/34366433 http://dx.doi.org/10.1016/j.ad.2021.07.005 Text en © 2021 AEDV. Published by Elsevier España, S.L.U. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Dermatología Práctica Morgado-Carrasco, D. Ibaceta-Ayala, J. Piquero-Casals, J. La hidroxicloroquina como fármaco fundamental en dermatología y su papel controvertido en la COVID-19 |
title | La hidroxicloroquina como fármaco fundamental en dermatología y su papel controvertido en la COVID-19 |
title_full | La hidroxicloroquina como fármaco fundamental en dermatología y su papel controvertido en la COVID-19 |
title_fullStr | La hidroxicloroquina como fármaco fundamental en dermatología y su papel controvertido en la COVID-19 |
title_full_unstemmed | La hidroxicloroquina como fármaco fundamental en dermatología y su papel controvertido en la COVID-19 |
title_short | La hidroxicloroquina como fármaco fundamental en dermatología y su papel controvertido en la COVID-19 |
title_sort | la hidroxicloroquina como fármaco fundamental en dermatología y su papel controvertido en la covid-19 |
topic | Dermatología Práctica |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326180/ https://www.ncbi.nlm.nih.gov/pubmed/34366433 http://dx.doi.org/10.1016/j.ad.2021.07.005 |
work_keys_str_mv | AT morgadocarrascod lahidroxicloroquinacomofarmacofundamentalendermatologiaysupapelcontrovertidoenlacovid19 AT ibacetaayalaj lahidroxicloroquinacomofarmacofundamentalendermatologiaysupapelcontrovertidoenlacovid19 AT piquerocasalsj lahidroxicloroquinacomofarmacofundamentalendermatologiaysupapelcontrovertidoenlacovid19 |